These observations are concordant with large‐scale Mendelian randomization studies that have shown that inhibiting IL‐6 signalling could reduce the risk of developing CHD 53 whilst inhibiting IL‐1 α/β may increase the risk of CHD 26. This evidence concerns the gene IL1A and coronary artery disorder.